Literature DB >> 3982631

Heterogeneity in dementia of the Alzheimer type: evidence of subgroups.

R Mayeux, Y Stern, S Spanton.   

Abstract

We reviewed records of 121 consecutive patients with dementia of the Alzheimer type. Patients with myoclonus or extrapyramidal signs had greater intellectual decline and functional impairment in daily activities. Among patients studied over 4 years, there were four groups: benign--little to no progression; myoclonic--severe intellectual decline and frequent mutism after younger onset; extrapyramidal--severe intellectual and functional decline and frequent psychotic symptoms; typical--a gradual progression of intellectual and functional decline, but without other distinguishing features. Except for the group with myoclonus, no subgroup was segregated by age at onset or other demographic variables. This study suggests that dementia of the Alzheimer type is heterogeneous, and that certain clinical manifestations may be useful in predicting outcome.

Entities:  

Mesh:

Year:  1985        PMID: 3982631     DOI: 10.1212/wnl.35.4.453

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  50 in total

Review 1.  Alzheimer's disease.

Authors:  M Rossor
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

2.  Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles.

Authors:  U M Mann; E Mohr; M Gearing; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

3.  The genetics of Alzheimer disease--a teasing problem.

Authors:  J L Haines
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

4.  High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes.

Authors:  U Finckh; T Müller-Thomsen; U Mann; C Eggers; J Marksteiner; W Meins; G Binetti; A Alberici; C Hock; R M Nitsch; A Gal
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

5.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

6.  Segregation analysis reveals evidence of a major gene for Alzheimer disease.

Authors:  L A Farrer; R H Myers; L Connor; L A Cupples; J H Growdon
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

7.  Seizures in Alzheimer disease: who, when, and how common?

Authors:  Nikolaos Scarmeas; Lawrence S Honig; Hyunmi Choi; Julio Cantero; Jason Brandt; Deborah Blacker; Marilyn Albert; Joan C Amatniek; Karen Marder; Karen Bell; W Allen Hauser; Yaakov Stern
Journal:  Arch Neurol       Date:  2009-08

8.  Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.

Authors:  G Lennox; J Lowe; M Landon; E J Byrne; R J Mayer; R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

9.  Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.

Authors:  M Itoh; K Meguro; T Fujiwara; J Hatazawa; R Iwata; K Ishiwata; T Takahashi; T Ido; H Sasaki
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

10.  Estimating the probability for major gene Alzheimer disease.

Authors:  L A Farrer; L A Cupples
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.